Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

News Market Reaction – APLS

+135.40%

5 alerts

+135.40% News Effect

+143.9% Peak in 0 min

+$1.26B Valuation Impact

$2.18B Market Cap

0.0x Rel. Volume

On the day this news was published, APLS gained 135.40%, reflecting a significant positive market reaction. Argus tracked a peak move of +143.9% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1.26B to the company's valuation, bringing the market cap to $2.18B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash offer per APLS share: $41.00 per share APLS CVR payments: two payments of $2.00 per share each CNTA cash offer per share: $38.00 in cash per share +2 more

5 metrics

Cash offer per APLS share $41.00 per share Biogen cash consideration for Apellis sale

APLS CVR payments two payments of $2.00 per share each Nontransferable CVR tied to SYFOVRE sales thresholds

CNTA cash offer per share $38.00 in cash per share Eli Lilly cash consideration for Centessa sale

CNTA CVR potential up to an aggregate of $9.00 Non-transferable CVR contingent on milestones

BIRD asset sale value $39 million Sale of Allbirds IP and certain assets to American Exchange Group

Market Reality Check

Price: $40.87 Vol: Volume 2,156,356 is sligh...

normal vol

$40.87 Last Close

Volume Volume 2,156,356 is slightly below 20-day average 2,336,380 (relative volume 0.92x). normal

Technical Price 17.09 is trading below 200-day MA at 22.43, well under longer-term trend.

Peers on Argus

APLS was up 0.71% with 4 biotech peers (e.g., SLNO, SRRK, MLTX, RARE) also movin...

4 Up

APLS was up 0.71% with 4 biotech peers (e.g., SLNO, SRRK, MLTX, RARE) also moving up, showing sector-wide strength (median peer move about 11.1%).

Common Catalyst Broader biotech momentum with at least one peer (SRRK) tied to an FDA BLA resubmission, though most momentum names lacked same-day news.

Historical Context

5 past events · Latest: Mar 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Board appointment	Positive	-1.2%	Pfizer veteran Mikael Dolsten joins board to bolster R&D leadership.
Feb 24	Earnings results	Neutral	-1.5%	Reported 2025 revenues, net income, Sobi upfront, and pipeline progress.
Feb 23	Conference appearance	Neutral	+0.8%	Announced TD Cowen health care conference fireside chat webcast details.
Feb 19	Scientific presentations	Positive	+2.7%	Macula Society talks including five-year GALE data for SYFOVRE.
Feb 10	Earnings call notice	Neutral	-1.1%	Scheduled Q4 and full-year 2025 results conference call and webcast.

Pattern Detected

Recent news has produced modest, often muted price reactions, with one divergence where positive board news coincided with a small price decline.

Recent Company History

Over the past months, Apellis issued board, financial, and scientific updates. A board appointment on Mar 1, 2026 and related 8-K and Form 3/4 filings underscored governance changes, while the Feb 24, 2026 earnings release detailed 2025 performance and ongoing trials. Scientific visibility increased through Macula Society presentations and conference appearances. Despite these developments, price moves stayed moderate, providing context as investors weigh today’s law firm investigation into the announced sale terms.

Market Pulse Summary

The stock surged +135.4% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +135.4% in the session following this news. A strong positive reaction aligns with broader biotech strength, as APLS traded above peers in an up sector while deal terms drew legal scrutiny. Historically, Apellis news produced modest moves, so a large gain would stand out versus prior reactions around -1% to +3%. Investors may weigh the announced $41.00 cash consideration plus CVRs against any perceived upside from further negotiations or legal actions.

Key Terms

contingent value right, federal securities laws, fiduciary duties, intellectual property

4 terms

contingent value right financial

"a nontransferable contingent value right for the right to receive two payments"

A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.

federal securities laws regulatory

"potential violations of the federal securities laws and/or breaches of fiduciary duties"

Federal securities laws are the set of national rules that require companies and market participants to provide accurate information, prohibit deceptive practices, and ensure fair trading of stocks and bonds. Think of them as the rules of the road for financial markets: they help investors make informed choices by mandating disclosures and punishing fraud, which reduces risk and builds trust in the safety and reliability of investments.

fiduciary duties regulatory

"violations of the federal securities laws and/or breaches of fiduciary duties to shareholders"

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

intellectual property technical

"Allbirds, Inc.'s (NASDAQ: BIRD)'s sale of its intellectual property and certain other assets"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

AI-generated analysis. Not financial advice.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, March 31, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.

Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.

Allbirds, Inc.'s (NASDAQ: BIRD)'s sale of its intellectual property and certain other assets to American Exchange Group for $39 million. If you are an Allbirds shareholder, click here to learn more about your legal rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/are-apls-cnta-bird-obtaining-fair-deals-for-their-shareholders-302730253.html

SOURCE Halper Sadeh LLP